INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 177 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $783,000 | +6.4% | 19,185 | -11.5% | 0.45% | +42.4% |
| Q1 2021 | $736,000 | +33.1% | 21,685 | +32.3% | 0.32% | +2.3% |
| Q4 2020 | $553,000 | -18.1% | 16,385 | -37.7% | 0.31% | -24.4% |
| Q3 2020 | $675,000 | +46.7% | 26,285 | +46.6% | 0.41% | +39.6% |
| Q2 2020 | $460,000 | +66.7% | 17,935 | 0.0% | 0.29% | +18.6% |
| Q1 2020 | $276,000 | -67.8% | 17,935 | -28.1% | 0.25% | -59.1% |
| Q4 2019 | $856,000 | – | 24,930 | – | 0.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |